Psychedelics reopen the social reward learning critical period.

Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, Wright N, Lama C, Faltin S, Goff LA, Stein-O'Brien GL, Dölen G. · 2023

Read Psychedelics reopen the social reward learning critical period. by Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, Wright N, Lama C, Faltin S, Goff LA, Stein-O'Brien GL, Dölen G. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10284704.txt.

Introduction

Nardou and colleagues report that psychedelic drugs reopen a critical period for social reward learning, in a 2023 study. Critical periods are windows early in life when the brain learns certain skills with ease, after which the window closes. Social reward learning, the pull of social approval, has such a window in mice and likely in humans.

The team found that several psychedelics reopen that window in adult mice. The reopening lasted from days to weeks depending on the drug. The result may explain why these drugs help in therapy that involves relearning social patterns.

Catalog record

CREATORNardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, Wright N, Lama C, Faltin S, Goff LA, Stein-O'Brien GL, Dölen G.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10284704

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Psychedelics reopen the social reward learning critical period By Romain Nardou, Edward Sawyer, Young Jun Song, Makenzie Wilkinson, Yasmin Padovan-Hernandez, Júnia Lara de Deus, Noelle Wright, Carine Lama, Sehr Faltin, Loyal A. Goff, Genevieve L. Stein-O’Brien, Gül Dölen Published in: Nature DOI: 10.1038/s41586-023-06204-3 ABSTRACT Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness1,2. These drugs have been used for millennia in both spiritual and medicinal contexts, and a number of recent clinical successes have spurred a renewed interest in developing psychedelic therapies3–9. Nevertheless, a unifying mechanism that can account for these shared phenomenological and therapeutic properties remains unknown. Here we demonstrate in mice that the ability to reopen the social reward learning critical period is a shared property across psychedelic drugs. Notably, the time course of critical period reopening is proportional to the duration of acute subjective effects reported in humans. Furthermore, the ability to reinstate social reward learning in adulthood is paralleled by metaplastic restoration of oxytocin-mediated long-term depression in the nucleus accumbens. Finally, identification of differentially expressed genes in the ‘open state’ versus the ‘closed state’ provides evidence that reorganization of the extracellular matrix is a common downstream mechanism underlying psychedelic drug-mediated critical period reopening. Together these results have important implications for the implementation of psychedelics in clinical practice, as well as the design of novel compounds for the treatment of neuropsychiatric disease. MAIN Classically, psychedelics have been defined to include drugs such as lysergic acid diethylamide (LSD), mescaline, phenylcyclohexyl piperidine (PCP), ibogaine, 3,4-methylenedioxymethamphetamine (MDMA), psylocibin and ketamine, because each of these compounds produces alterations to sensory, self, time and space perception that are “so alien to everyday experience that they shed new light on the workings of these everyday mental functions”1. Although more recent attempts have been made to subcategorize psychedelics10 on the basis of the subjective character of the altered state that they induce (for example, hallucinogenic, empathogenic, oneirogenic or dissociative), their chemical structure (for example, tryptamines, phenethylamines or arylcyclohexamines), or their principal binding target (for example, serotonin receptor 2A (5-HT2AR), monoamine transporter, κ-opioid receptor (KOR) or N-methyl-d-aspartate receptor (NMDAR)), the importance of these categories for therapeutic applications remains unclear, since psychedelics that span the diversity of classification systems have shown remarkable promise for the treatment of addiction4,5, post-traumatic stress disorder6,7 (PTSD) and depression3,8,9. Thus, identification of a common neurobiological mechanism that can account for the shared therapeutic effects of psychedelics is an obvious priority for translational neuroscience. During specific periods of brain development, the nervous system exhibits heightened sensitivity to ethologically relevant stimuli, as well as increased malleability for synaptic, circuit and behavioural modifications. These mechanistically constrained windows of time are called critical periods and neuroscientists have long sought methods to reopen them for therapeutic benefit. Recently, we have discovered a novel critical period for social reward learning and shown that the empathogenic psychedelic MDMA is able to reopen this critical period11. This mechanism shares a number of features with the therapeutic effects of MDMA-assisted psychotherapy for the treatment of PTSD, including rapid onset, durability and context dependence6,7. At the same time, cocaine does not reopen the social reward learning critical period11, and since cocaine does not share the psychedelics’ therapeutic profile12, these results lend further support for the view that the reinstatement of social reward learning in adulthood underlies the therapeutic efficacy of MDMA. Whether the ability of MDMA to reopen the critical period for social reward learning generalizes across psychedelics remains an open question. MDMA is classified as an ‘empathogen’ because its acute subjective effects are distinctly prosocial in quality13. The fact that this quality is not shared by hallucinogenic psychedelics such as psilocybin and LSD14, dissociative psychedelics such as ketamine15, or oneirogenic psychedelics such as ibogaine16 challenges the idea that these drugs could reopen the social reward learning critical period. However, the psychotropic effects of MDMA include an altered state of consciousness shared by all psychedelics1,2, and if it is this characteristic rather than its prosocial properties that embodies the subjective experience of reopening critical periods, then the ability to reinstate social reward learning in adulthood might generalize across psychedelics. CRITICAL PERIOD REOPENING IS A SHARED PROPERTY To test whether the ability of MDMA to reopen the social reward learning critical period generalizes across psychedelics, we began by examining the effect of psilocybin pretreatment on the magnitude of social reward learning in adulthood using the social reward conditioned place preference (sCPP) assay (Extended Data Fig. 1). We administered a single intraperitoneal (i.p.) dose of psilocybin17 (0.3 mg kg−1) to adult male mice (at postnatal day 96 (P96)) and 48 h later (at P98), we assessed the magnitude of sCPP (Fig. 1a). Mice pretreated with psilocybin, but not saline, exhibited a significant sCPP at P98 (Fig. 1b–d). To formally designate ‘open’ and ‘closed’ states of this critical period, we next generated a natural spline regression model to previously published data11 with knots at P35 and P98 (P = 1.003 × 10−6; root mean square error (r.m.s.e.) = 0.19; R2 = 0.11), as shown in Extended Data Fig. 2. When compared with this derived curve, the magnitude of sCPP in saline-treated mice did not deviate significantly from the closed state (P = 0.72), whereas the fit derived from psilocybin-treated mice demonstrated a significant mean shift (P = 1.12 × 10−6) in range of the open state (Fig. 1e). Similarly, pretreatment with LSD17 (i.p. 1 µg kg−1) but not saline, also reopened the critical period for social reward learning (saline P = 0.90, LSD P = 1.76 × 10−9) (Fig. 1f–i). Next, we examined the effects of ketamine18 (i.p. 3 mg kg−1) and ibogaine19 (i.p. 40 mg kg−1). Mice pretreated with either drug also exhibited sCPP in adulthood (P = 8.78 × 10−4 and P = 3.17 × 10−5, respectively) (Fig. 1k–m). As with MDMA11, these effects were dose-dependent (Extended Data Fig. 3). In juveniles, MDMA11 (i.p. 10 mg kg−1) pretreatment did not lead to a further increase the magnitude of social reward learning (Extended Data Fig. 3). In contrast to its effects on social reward learning behaviour, pretreatment with psychedelics had no effect on the magnitude of two addiction-like behaviours: cocaine reward learning and amphetamine-induced locomotor sensitization (Extended Data Fig. 4). Together, these studies demonstrate that as with empathogenic psychedelics11, hallucinogenic, oneirogenic and dissociative psychedelics are able to reopen the critical period for social reward learning.Fig. 1Psychedelics reopen the social reward learning critical period.a, Experimental time course of i.p. pretreatment (Rx) in sCPP. b,c,f,g,j,k, Individual (top) and average (bottom) responses of P98 mice indicate that mice pretreated with psilocybin (0.3 mg kg−1) (c; n = 15, t(14) = −3.741, P = 0.002), LSD (1 µg kg−1) (g; n = 9, t(8) = −7.095, P < 0.001), ketamine (3 mg kg−1) (j; n = 18, t(17) = −3.826, P < 0.002), and ibogaine (40 mg kg−1) (k; n = 12, t(11) = −2.690, P = 0.02) but not saline (b; n = 17 mice, t(16) = −0.441, P = 0.665. f; n = 14 mice, t(13) = −1.215, P = 0.25) develop a preference for the social bedding cue. Two-tailed paired t-test. d,h,l, Comparisons reveal a significant increase in normalized (top) and subtracted (bottom) social preference

Read the complete text